Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Intratumoral levering av virale replikon (saRNA) partikler som uttrykker IL-12 i hode- og nakkekreft

15. september 2026 oppdatert av: VLP Therapeutics

Studie av intratumorale injeksjoner av VLPONC-01 i hode- og nakkekreft

The goal of this clinical trial is to assess the safety and tolerability of a virus replicon particle (VRP) encapsulated saRNA encoding IL-12 when injected into in head and neck cancer patients. The main questions being addressed are:

The safety and tolerability of intratumoral (IT) injections of VRP-encapsulated saRNA encoding IL-12 (VLPONC-01)

The tumor response to IT injections of VLPONC-01

The tumor response due to the combination of IT injections of VLPONC-01 and system IV administration of neoadjuvant pembrolizumab (anti-PD-1) treatment

Researchers will compare neoadjuvant pembrolizumab alone to the combination therapy to see if the combination enhances tumor responses.

Studieoversikt

Detaljert beskrivelse

The study is an Open label, Phase I study to determine the safety of IT injected VLPONC-01 as a therapeutic agent in subjects with non-resectable and resectable Head and Neck Cancer Squamous Cell Carcinomas (HCSCC), and secondarily to assess pathologic response and radiological response (assessed by RECIST 1.1 criteria) in the primary tumor and regional lymph nodes. Researchers also will explore tumor microenvironment changes in cytokine levels and cellular responses.

There will be three distinct cohorts enrolling sequentially:

Cohort A: Researchers will enroll unresectable or recurrent/metastatic head and neck cancer with at least 1 injectable tumor not scheduled for tumor resection surgery who will receive four doses of VLPONC-01.

Cohort C: Researchers will enroll HCSCC patients scheduled for tumor resection surgery who will receive four doses of VLPONC-1 and two doses of neoadjuvant pembrolizumab or only two doses of neoadjuvant pembrolizumab prior to tumor resection surgery.

Studietype

Intervensjonell

Registrering (Antatt)

41

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Stanford, California, Forente stater, 34305
        • Rekruttering
        • Stanford University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Fred M Baik, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Cohort A - Unresectable or recurrent/metastatic head and neck cancer with at least 1 injectable tumor not scheduled for tumor resection surgery. With one the following prior treatments:

    Subjects must have received a platinum containing chemotherapy regimen, 5-Fluorouracil chemotherapy, taxane based chemotherapy, cetuximab or gemcitabine for treatment of primary tumor in locally advanced, or metastatic settings.

    Subjects must have received an anti-PD-1/ PD-L1 as monotherapy or in combination with chemotherapy.

    Subjects must have progressed following therapy with at least one PD-1 or PD-L1 checkpoint inhibitor (regardless of PD-L1 expression status).

    Prior progression on a PD-1 or PD-L1 checkpoint inhibitor should be unequivocal; progression that occurs within the first 8 weeks of treatment on these agents should be confirmed with a second CT at least 4 weeks apart (to exclude pseudo-progression).

    Patients with activating EGFR mutation or ALK rearrangement which is expected to be responsive to available tyrosine kinase inhibitor therapy, therefore these subjects must have been previously treated with an applicable tyrosine kinase inhibitor.

    OR Cohort C - Patients with at least 1 measurable resectable lesion clinical stage I-IVb (cT1-4, N0-3) (AJCC, 8th Edition) (Amin, 2017), Histologically or cytologically confirmed HNSCC. Scheduled to undergo tumor surgical resection of the primary tumor.

  2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and adequate bone marrow and organ function.

  3. Primary tumors should be amenable to intratumoral (IT) injection >1 cm diameter. This will be determined by the Protocol Director, or the surgeon involved.

  4. Subjects with either a local recurrence or a new primary tumor will be allowed.

  5. Age ≥ 18 years.

  6. Have acceptable organ and marrow function defined as follows:

    Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Hemoglobin ≥ 8.0 g/dL (Note: use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable) Total bilirubin ≤2x institutional upper limit of normal (ULN) AST(SGOT) or ALT(SGPT) ≤ 3.0x institutional ULN

  7. Ability to understand and the willingness to provide written informed consent.

  8. Life expectancy > 12 weeks (about 3 months).

  9. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

  1. Tumors which are not feasible for injections include high risk lesions that are near vital organs or important neurovascular structures, as determined by the Protocol Director or involved surgeon.
  2. Women of childbearing potential must have a negative serum β-hCG pregnancy test within 7 days prior to the administration of the first study treatment and/or urine pregnancy 48 hours prior to the administration of the first study treatment. Both sexually active women of childbearing potential and males (and their female partners) patients must agree to use two methods of effective contraception, one of them being a barrier method, or to abstain from sexual activity during the study and for at least 6 months after last dose of study drugs.
  3. Patients expected to receive other anti-cancer medication such as, chemotherapy, immunotherapy, biologic therapy, targeted therapy, monoclonal antibodies, hormonal therapy (other than leuprolide or other GnRH agonists) prior to surgery and where all acute toxicity of prior treatments have not resolved.
  4. Participation in another clinical study with an investigational product during the last 30 days.
  5. Uncontrolled intercurrent illness including, that do not respond to active medical intervention.
  6. Current or prior use of immunosuppressive medication within 28 days before the first dose of injection, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid.
  7. If applicable: Women who are breastfeeding.
  8. History of allogenic organ transplant that requires use of immunosuppressives.
  9. Subject has active or uncontrolled infection including known HIV infection or known chronic hepatitis B or C.
  10. Any condition that, in the investigator's opinion, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
  11. Uncontrolled intercurrent illness including those that do not respond to active medical intervention.
  12. Any contraindication to the use of known history of hypersensitivity to any immune therapy's drugs.
  13. Subjects must not have received any live vaccine within 28 days prior to the first dose of study treatment.
  14. Active autoimmune disease that requires systemic therapy, in the Investigator's opinion, may increase the risk of study participation.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Cohort A (1 x 10^9 viral particles per injection)

Recurrent or Metastatic Head and Neck Cancer not scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly, with an additional follow-up safety visit 30 and 90 days post the final injection.

Weekly IT injections of 1 x 10^9 viral particles of VLPONC-01

Andre navn:
  • VLPONC-01
  • IL-12 saRNA
  • VRP-IL-12
Eksperimentell: Cohort C - Group 1 (1 x 10^9 viral particles per injection plus Pembrolizumab)

Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly and 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery, follow-up safety visit 30 days post-surgery and 90 days post final treatment.

Weekly IT injections of 1 x 10^9 viral particles of VLPONC-01

Andre navn:
  • VLPONC-01
  • IL-12 saRNA
  • VRP-IL-12

200mg twice 3 weeks apart IV

Andre navn:
  • Pembrolizumab
Eksperimentell: Cohort C - Group 2 (3 x 10^8 viral particles per injection plus Pembrolizumab)

Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly and 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery follow-up safety visit 30 days post-surgery and 90 days post final treatment.

200mg twice 3 weeks apart IV

Andre navn:
  • Pembrolizumab

Weekly IT injections of 3 x 10^8 viral particles of VLPONC-01

Andre navn:
  • VLPONC-01
  • IL-12 saRNA
  • VRP-IL-12
Eksperimentell: Cohort C - Pembrolizumab only

Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery, follow-up safety visit 30 days post-surgery and 90 days post final treatment.

200mg twice 3 weeks apart IV

Andre navn:
  • Pembrolizumab

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety and tolerability
Tidsramme: First injection to 90-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)

To assess the safety and tolerability of VLPONC-01. Safety will be based on the occurrence of any grade 3 or higher drug-related adverse events from the VLPONC-01 injections for non-surgery patients and any grade 3 or higher drug-related adverse events that result in a delay to tumor resection surgery.

First injection to 90-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Levels of circulating IL-12
Tidsramme: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)

To assess the circulating blood levels of IL-12 after VLPONC-01 treatment compared to baseline to determine the occurrence and safety profile of potential systemic inflammatory responses.

First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)
VLPONC-01 levels in tumor tissue
Tidsramme: First injection to tumor resection surgery

To detect levels of VLPONC-01 RNA in surgically resected tissue.

First injection to tumor resection surgery
Radiological Tumor Response
Tidsramme: First injection to tumor resection surgery (up to 3 months)

To assess the primary tumor response by RECIST.

First injection to tumor resection surgery (up to 3 months)
Pathological Tumor Response
Tidsramme: First injection to tumor resection surgery (up to 3 months)

To assess the primary tumor response by pathological analysis.

First injection to tumor resection surgery (up to 3 months)

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Circulating levels of cytokines, chemokines, and immune markers
Tidsramme: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.

To assess the circulating levels cytokines, chemokines, and immune markers using a proteomics assay.

First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
ICH Changes in Tumor microenvironment
Tidsramme: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.

To assess levels of CD8+ T-cells, macrophages, and other immune cell populations in surgically resected tissue compared to biopsy tissue using immunohistochemistry.

First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
Changes in ctDNA related to Neoadjuvant treatment
Tidsramme: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.

To assess changes in ctDNA MRD treatment-related molecular response (Cohort C).

First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
Changes in cellular populations
Tidsramme: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.

To assess the changes in cellular populations in circulating blood using flow cytometry.

First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Fred M Baik, MD, Stanford University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. mai 2025

Primær fullføring (Antatt)

30. desember 2027

Studiet fullført (Antatt)

30. desember 2027

Datoer for studieregistrering

Først innsendt

11. desember 2024

Først innsendt som oppfylte QC-kriteriene

11. desember 2024

Først lagt ut (Faktiske)

16. desember 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

21. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere